NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

Phase 1

Completed

Conditions: Neoplasms
Pancreatic Neoplasms

Interventions: Drug: LMB-100
Drug: Nab-Paclitaxel
Device: Mesothelin Expression

First Posted Date: 2016-06-23

Last Posted Date: 2022-03-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT02810418

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Phase 1

Completed

Conditions: Mesothelioma

Interventions: Drug: LMB-100
Drug: nab-paclitaxel

First Posted Date: 2016-06-14

Last Posted Date: 2022-08-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT02798536

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: CNS 2a
CNS 2b
CNS 2c
CNS1
Recurrent Adult Acute Myeloid Leukemia
Recurrent Childhood Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Biological: Filgrastim
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: WEE1 Inhibitor AZD1775

First Posted Date: 2016-06-07

Last Posted Date: 2017-05-03

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02791919

Helicobacter Pylori Genome Project (HpGP)

Terminated

Conditions: Non-Atrophic Gastritis
Intestinal Metaplasia
Gastric Cancer

First Posted Date: 2016-06-02

Last Posted Date: 2020-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1000

Registration Number: NCT02788214

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇮🇩
University of Indonesia, Kota Depok, Indonesia

and more 89 locations

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

Phase 2

Completed

Conditions: Bladder Cancer
Urinary Bladder Neoplasms
Urothelial Carcinoma

Interventions: Drug: 75 approved agents
Other: COXEN

First Posted Date: 2016-06-02

Last Posted Date: 2020-11-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT02788201

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia

Phase 2

Active, not recruiting

Conditions: Chronic Atrophic Gastritis
Gastric Carcinoma

Interventions: Drug: Curcumin
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Other: Quality-of-Life Assessment

First Posted Date: 2016-05-26

Last Posted Date: 2025-04-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT02782949

Locations: 🇭🇳
Hospital Regional de Occidente, Santa Rosa De Copan, Honduras
🇵🇷
University of Puerto Rico, San Juan, Puerto Rico

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Phase 1

Completed

Conditions: Brain Stem Neoplasm
Pineal Region Neoplasm
Recurrent Lymphoma
Recurrent Malignant Solid Neoplasm
Recurrent Primary Central Nervous System Neoplasm
Recurrent Visual Pathway Glioma
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Primary Central Nervous System Neoplasm
Refractory Visual Pathway Glioma

Interventions: Drug: Entinostat
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2016-05-24

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT02780804

Locations: 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 18 locations

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Desmoplastic Melanoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Elastography
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2016-05-18

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT02775851

Locations: 🇺🇸
HaysMed, Hays, Kansas, United States
🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States

and more 278 locations

Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma

Phase 1

Completed

Conditions: Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7

Interventions: Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2016-05-18

Last Posted Date: 2022-06-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT02775812

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 66 locations

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Phase 1

Active, not recruiting

Conditions: Chronic Hepatitis
Hepatitis C Infection
Hepatocellular Carcinoma

Interventions: Biological: Electroporation-Mediated Plasmid DNA Vaccine Therapy
Biological: HCV DNA Vaccine INO-8000
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Biological: Rocakinogene Sifuplasmid

First Posted Date: 2016-05-13

Last Posted Date: 2025-03-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT02772003

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

and more 2 locations

Home Terms & Conditions Privacy Policy